financetom
Business
financetom
/
Business
/
S&P Global Enhances Capital IQ Pro with Expanded Fixed Income, Biopharma and Private Markets Data Content and AI Capabilities
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
S&P Global Enhances Capital IQ Pro with Expanded Fixed Income, Biopharma and Private Markets Data Content and AI Capabilities
Mar 12, 2026 5:48 AM

Drift AI acquisition and the integration of ProntoNLP boost platform's GenAI tooling for enhanced client impact

Adds ProntoNLP sentiment analysis to AI-powered Document Intelligence and over 4 million structured securities to accelerate financial analysis Acquires Drift AI to integrate natural language financial modeling into Capital IQ Pro Excel Plugin NEW YORK, March 12, 2026 /PRNewswire/ -- S&P Global today announced significant enhancements to its flagship S&P Capital IQ Pro platform that incorporate advanced artificial intelligence capabilities and expanded datasets to accelerate financial analysis and decision making. The updates include the addition of ProntoNLP analytics along with data expansions across fixed income, biopharma and private markets. Additionally, S&P Global ( SPGI ) announced the acquisition of Drift AI, an AI-powered Excel solution, with planned integration into the platform.

The enhancements reinforce S&P Capital IQ Pro's position as a comprehensive platform that delivers trusted data, connected technology and AI-powered tools that support research, client coverage, idea generation and risk management workflows. 

AI-Powered Research Acceleration

S&P Capital IQ Pro now includes ProntoNLP advanced sentiment analysis within Document Intelligence, Capital IQ Pro's AI-powered document analysis tool—enabling users to quickly access and assess the important themes and related sentiment in earnings call transcripts and associated documents. The enhanced functionality builds on S&P Global's ( SPGI ) 2025 acquisition of ProntoNLP, which brought advanced AI and NLP capabilities to better analyze and gain insights from textual data.

"We continue to deliver new AI-powered capabilities directly into Capital IQ Pro while also unlocking the platform to support new and compelling agentic use cases and opportunities," said Warren Breakstone, Head of Data & Research at S&P Market Intelligence. "The addition of ProntoNLP, and now DriftAI, are two of the latest examples of recent advancements. At the same time, we continue to invest heavily in adding new and differentiated data to enhance client decision making and bring these AI-powered capabilities to life."

Enhanced Data Coverage Across Key Markets

Additional data and capabilities expand the platform's analytical depth across multiple asset classes:

Expansion of Fixed Income Coverage: Added over 4 million structured securities from Markit, featuring enhanced pricing, analytics and liquidity data, along with more granular reference information such as collateral type and advisor roles. In previous releases, 20 million+ Fixed Income Securities across Loans, Munis, Government, Sovereign, Agency and Corporates (GSAC) were added to the platform.Security-Level Fixed Income Ownership Data: New granular ownership insights provide detailed holder information at the individual security level, enabling fixed income analysts to track institutional positioning, identify concentration risks and understand ownership patterns across bond markets.Visible Alpha Biopharma: Integration of comprehensive pharmaceutical sector coverage delivers specialized analytics including drug pipeline data, clinical trial insights, regulatory timelines and market forecasts to support investment decisions in the rapidly evolving healthcare sector.Expanded Private Markets Collection: Added 20,000 Investment Committee meeting packs, tender documents and LP filings to Gen-AI powered Document Intelligence. This is the first major integration of With Intelligence content into Capital IQ Pro and allows users to assess LP allocation strategies, track their evolution over time and help GPs inform their fundraising processes.Expanded Headcount Analytics: The platform now provides broader coverage of workforce-based metrics for evaluating companies when private company financial data is limited, featuring more intuitive connectivity between fund sponsors, funds and fund managers' screening results.Drift AI Acquisition

S&P Global ( SPGI ) acquired Drift AI (formerly Arkifi), an AI-powered Excel analysis solution that automates financial modeling workflows. The acquisition further accelerates AI enhancements in S&P Capital IQ Pro with plans to integrate Drift AI capabilities into the Capital IQ Pro Excel Plugin. Drift AI's technology enables natural language building and querying of financial models, enriches spreadsheets with contextual insights and helps users quickly identify trends, validate assumptions and cross-check materials.

For more information on S&P Capital IQ Pro, please see here.

To learn more about Artificial Intelligence at S&P Global ( SPGI ), please visit here.

Media Contacts:

Orla O'Brien

S&P Global ( SPGI )

+1 857 407 8559

[email protected]

Florence Bogitsh

S&P Global Market Intelligence

+1 646 460-7204

[email protected]

[email protected]

About S&P Global ( SPGI ) 

S&P Global ( SPGI ) enables businesses, governments, and individuals with trusted data, expertise and technology to make decisions with conviction. We are Advancing Essential Intelligence through world-leading benchmarks, data, and insights that customers need in order to plan confidently, act decisively, and thrive economically in a rapidly changing global landscape.   

From helping our customers assess new investments across the capital and commodities markets to guiding them through the energy expansion, acceleration of artificial intelligence, and evolution of public and private markets, we enable the world's leading organizations to unlock opportunities, solve challenges, and plan for tomorrow – today. Learn more at www.spglobal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/sp-global-enhances-capital-iq-pro-with-expanded-fixed-income-biopharma-and-private-markets-data-content-and-ai-capabilities-302711573.html

SOURCE S&P Global ( SPGI )

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ondas to Acquire Roboteam, Expanding Market Footprint and Multi-Domain Autonomy with Field-Proven Tactical Ground Robotics
Ondas to Acquire Roboteam, Expanding Market Footprint and Multi-Domain Autonomy with Field-Proven Tactical Ground Robotics
Nov 25, 2025
Expands OAS's mission portfolio with Roboteam's rugged, multi-mission tactical ground robotics deployed by leading global defense customers Roboteam's established deployments with leading militaries across 30 countries expected to provide Ondas ( ONDS ) with a mature pipeline and accelerated access to priority defense programs Ondas ( ONDS ) expects Roboteam to add $3 - 4 million in revenue in Q4...
New Generation Consumer Group Provides Corporate Update as Due Diligence Advances on Spiritual Glow Acquisition
New Generation Consumer Group Provides Corporate Update as Due Diligence Advances on Spiritual Glow Acquisition
Nov 25, 2025
PHOENIX, AZ / ACCESS Newswire / November 25, 2025 / New Generation Consumer Group, Inc. ( NGCG ) today issued a corporate update as the Company continues moving through the due diligence phase related to the proposed acquisition of a 51% controlling interest in the Spiritual Glow digital brand. Management reports that the development team is actively expanding NGCG's existing...
Biogen, Eisai Submit Supplemental Biologics License Application to FDA for Weekly Lecanemab Injections
Biogen, Eisai Submit Supplemental Biologics License Application to FDA for Weekly Lecanemab Injections
Nov 25, 2025
08:24 AM EST, 11/25/2025 (MT Newswires) -- Biogen (BIIB) and Eisai said Tuesday Eisai has completed the rolling submission of a supplemental Biologics License Application to the US Food and Drug Administration seeking approval for a weekly subcutaneous starting dose of lecanemab-irmb. The companies said the treatment is approved for Alzheimer's patients in the mild cognitive impairment or mild dementia...
LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment
LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment
Nov 25, 2025
Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( LIXT ) a biotech company focused on advancing cancer treatments, today announced it has completed the acquisition of Liora Technologies Europe...
Copyright 2023-2026 - www.financetom.com All Rights Reserved